Are patients with systemic lupus erythematosus at increased risk for COVID-19?

Ann Rheum Dis. 2021 Feb;80(2):e25. doi: 10.1136/annrheumdis-2020-217787. Epub 2020 May 25.

Authors

Ennio Giulio Favalli¹, Maria Gerosa^{2

3}, Antonella Murgo², Roberto Caporali^{2

3}

Affiliations

¹ Division of Clinical Rheumatology, Gaetano Pini-CTO, Milano, Lombardia, Italy ennio.favalli@gmail.com.
² Division of Clinical Rheumatology, Gaetano Pini-CTO, Milano, Lombardia, Italy.
³ Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milano, Lombardia, Italy.

PMID: 32451344
DOI: 10.1136/annrheumdis-2020-217787

No abstract available

Keywords: antirheumatic agents; hydroxychloroquine; lupus erythematosus, systemic.

Publication types

Letter
Comment

MeSH terms

COVID-19*
Coronavirus*
Humans
Hydroxychloroquine
Lupus Erythematosus, Systemic*
SARS-CoV-2

Substances

Hydroxychloroquine